What effect does ivonib have on leukemic IDH mutant gliomas?

Ivosidenib is a selective IDH1 inhibitor, mainly used to treat tumors carrying IDH1 gene mutations. IDH1mutations can lead to the overproduction of 2-hydroxyglutarate (2-HG), interfere with normal cell differentiation, and promote cancer. Ivonib inhibits the activity of mutated IDH1 enzyme and reduces the production of 2-HG, thereby restoring cell differentiation. This mechanism has shown important therapeutic value in certain types of leukemia and glioma.

About 6-10%of patients with acute myeloid leukemia (AML) have IDH1 mutations. For these patients, ivonib has shown the ability to induce remission in multiple clinical studies, especially in relapsed or refractory AML. A key clinical trial (AG120-C-001) shows that ivosidenib treatment can achieve complete remission or hematological remission in some patients. Some patients can even postpone bone marrow transplantation after treatment and extend their survival time.

IDH1mutations are particularly common in low-grade gliomas, with approximately 70-80% of patients with diffuse astrocytoma and oligodendroglioma carrying this mutation. The research of ivosidenib in this type of glioma is still in the exploratory stage, but preliminary results show that ivosidenib can effectively reduce the level of 2-HG in tumor tissue, and some patients have stable disease or even tumor shrinkage. This provides an alternative treatment option for patients who cannot undergo chemoradiotherapy.

Although ivonib has achieved initial success in IDH1 mutated tumors, the persistence of efficacy and resistance mechanisms are still the focus of research. A number of clinical trials are currently exploring the combination of ivonib with other targeted drugs, immunotherapy or chemotherapy, in order to enhance the efficacy and delay the occurrence of drug resistance. Overall, ivonib brings new treatment hope to patients with IDH1 mutation-related leukemia and glioma, but long-term efficacy and individualized strategies still require further data support.

Reference link:https://www.tibsovo.com/

xa0